Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
38.00
-2.33 (-5.78%)
Mar 31, 2025, 11:00 AM EDT - Market open

Monopar Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2015
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2015
Selling, General & Admin
2.883.232.952.632.442.36
Upgrade
Research & Development
4.125.67.596.494.071.97
Upgrade
Operating Expenses
78.8310.549.136.514.32
Upgrade
Operating Income
-7-8.83-10.54-9.13-6.51-4.32
Upgrade
Interest & Investment Income
0.350.430.020.020.080.1
Upgrade
EBT Excluding Unusual Items
-6.47-8.4-10.52-9.1-6.43-4.22
Upgrade
Other Unusual Items
----0.12-
Upgrade
Pretax Income
-6.47-8.4-10.52-9.1-6.3-4.22
Upgrade
Net Income
-6.47-8.4-10.52-9.1-6.3-4.22
Upgrade
Net Income to Common
-6.47-8.4-10.52-9.1-6.3-4.22
Upgrade
Shares Outstanding (Basic)
333222
Upgrade
Shares Outstanding (Diluted)
333222
Upgrade
Shares Change (YoY)
23.15%8.70%1.97%13.82%17.56%0.32%
Upgrade
EPS (Basic)
-1.96-3.04-4.13-3.65-2.88-2.27
Upgrade
EPS (Diluted)
-1.96-3.04-4.13-3.65-2.88-2.27
Upgrade
EBIT
-7-8.83-10.54-9.13-6.51-4.32
Upgrade
Updated Nov 8, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q